Search results
Indian drugmakers to see FY25 revenue boost in key US market, says India Ratings and Research
Reuters via Yahoo News· 3 minutes agoIndia is a hub of bulk generic drug manufacturing and drugmakers including Dr Reddy's, Cipla, Sun...
Big Pharma Teva Accused of Delaying Generic Drug Competition | Connecticut Law Tribune
Law.com· 5 days agoLawsuits against large pharmaceutical companies alleging the use of inaccurate patent listings to...
Hims Debuts $199 Weight-Loss Shots at 85% Discount to Wegovy
Bloomberg via Yahoo Finance· 7 days ago(Bloomberg) -- In just a few years, Hims & Hers Health Inc. reached almost $1 billion in sales by...
Cipla receives final approval for the generic version of Somatuline® Depot (Lanreotide) Injection...
FOX 5 San Diego· 5 days agoCipla's Lanreotide Injection is AP-rated therapeutic equivalent generic version of Somatuline® Depot (Lanreotide) Injection.
McKesson (MCK) Hits 52-Week High: What's Driving the Stock?
Zacks· 6 days agoFree Report) scaled a new 52-week high of $566.16 on May 20, 2024, before closing the session marginally lower at $564. The company’s long-term expected growth rate of 13.5% ...
Congress evaluate how to lower prescription prices by increasing competition
WSOC-TV Charlotte· 5 days agoRoughly 30 percent of Americans say they’re struggling to pay for prescription drugs. “My doctors have me on a four drug combination with a list price of more than one million ...
How Drug Companies Stifle Competition With ‘Product Hopping’
Forbes· 6 days agoActavis had spent that sum to acquire Forest and its portfolio of pharmaceutical products. Forest...
Pay for Delay Is Sometimes Okay | JD Supra
JD Supra· 3 days agoThe US Court of Appeals for the Second Circuit affirmed the dismissal of a lawsuit against pharmaceutical companies accused of violating antitrust laws by using reverse payments to delay entry ...
Viatris Inc's Dividend Analysis
GuruFocus.com via Yahoo Finance· 5 days agoViatris Inc (NASDAQ:VTRS) recently announced a dividend of $0.12 per share, payable on 2024-06-14, with the ex-dividend date set for 2024-05-23. As...
Hims & Hers Health says it will offer compounded GLP-1 injections
NBC Universal via AOL· 7 days agoHims & Hers CEO Andrew Dudum told CNBC that the company is “confident” that customers will be able...